Search

Displaying results 5451 - 5460 of 10000 in total
  1. Pathway

    Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/16:0)

    smpdb.ca/view/SMP0015377
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine +1 more
  2. Pathway

    Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:0)

    smpdb.ca/view/SMP0015379
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine +1 more
  3. Pathway

    Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/24:0)

    smpdb.ca/view/SMP0015401
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine +1 more
  4. Pathway

    Phosphatidylethanolamine Biosynthesis PE(20:0/18:4(6Z,9Z,12Z,15Z))

    smpdb.ca/view/SMP0015414
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine +1 more
  5. Pathway

    Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:3(9Z,12Z,15Z))

    smpdb.ca/view/SMP0015442
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine +1 more
  6. Pathway

    Acylcarnitine (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine

    smpdb.ca/view/SMP0124408
    Metabolic

    (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is an acylcarnitine. … once again form (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl-CoA and L-carnitine. (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl-CoA then enters into the mitochondrial

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
  7. Drug

    Sulfaphenazole

    go.drugbank.com/drugs/DB06729
    Approved

    Sulfaphenazole is a sulfonamide antibacterial.

    Categories: Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors
  8. Drug

    Thonzonium

    go.drugbank.com/drugs/DB09552
    Approved

    It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. … A common pharmaceutical formulation of thonzonium bromide is cortisporin-TC ear drops. It is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone.

  9. Drug

    Mexiletine

    go.drugbank.com/drugs/DB00379
    ApprovedInvestigational

    Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  10. Drug

    Vibostolimab

    go.drugbank.com/drugs/DB16420
    Investigational

    Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK